Recently, new antigen targets are being explored in ongoing clinical trials: Tepoditamab (MCLA-117), a BiTE targeting CD3, and CLEC12A, an antigen present on leukemic stem cells and leukemic blasts whose expression seems stable throughout diagnosis, treatment, and relapse [56], showed, as early clinical results, an ORR of 10.3% with a MLFS rate of 1.7% and a CRS rate of 36.2% (≥grade 3 in 8.6%) [57]; and CLN-049, a FLT3 × CD3 BiTE, which showed high efficacy against human leukemic cell lines and patient-derived AML in mouse xenograft models [58]. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.